These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial. Knorr UB Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724 [TBL] [Abstract][Full Text] [Related]
45. An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder. Pierò A; Locati E Hum Psychopharmacol; 2011 Jan; 26(1):63-71. PubMed ID: 21305612 [TBL] [Abstract][Full Text] [Related]
46. Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant? Gerra ML; Marchesi C; Amat JA; Blier P; Hellerstein DJ; Stewart JW J Clin Psychiatry; 2014 Sep; 75(9):e939-44. PubMed ID: 25295437 [TBL] [Abstract][Full Text] [Related]
48. Two types of aggression are differentially related to serotonergic activity and the A779C TPH polymorphism. Hennig J; Reuter M; Netter P; Burk C; Landt O Behav Neurosci; 2005 Feb; 119(1):16-25. PubMed ID: 15727508 [TBL] [Abstract][Full Text] [Related]
49. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Ashina S; Bendtsen L; Jensen R Pain; 2004 Mar; 108(1-2):108-14. PubMed ID: 15109513 [TBL] [Abstract][Full Text] [Related]
50. Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study. Van Holten TC; Roest M; Riphagen J; Jansen C; Naarding P; Adriaansen HJ; De Groot PG; Remijn JA J Thromb Haemost; 2012 Jun; 10(6):1177-9. PubMed ID: 22429872 [No Abstract] [Full Text] [Related]
51. [Panic disorder--psychobiological aspects of personality dimensions]. Draganić-Rajić S; Lecić-Tosevski D; Paunović VR; Cvejić V; Svrakić D Srp Arh Celok Lek; 2005; 133(3-4):129-33. PubMed ID: 16206699 [TBL] [Abstract][Full Text] [Related]
52. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Bandelow B; Stein DJ; Dolberg OT; Andersen HF; Baldwin DS Pharmacopsychiatry; 2007 Jul; 40(4):152-6. PubMed ID: 17694478 [TBL] [Abstract][Full Text] [Related]
53. Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin αIIbβ3-mediated signaling in human platelets. Tseng YL; Braun A; Chang JP; Chiang ML; Tseng CY; Chen W Toxicol Appl Pharmacol; 2019 Feb; 364():106-113. PubMed ID: 30592962 [TBL] [Abstract][Full Text] [Related]
54. The role of SSRIs in panic disorder. Sheehan DV; Harnett-Sheehan K J Clin Psychiatry; 1996; 57 Suppl 10():51-8; discussion 59-60. PubMed ID: 8917132 [TBL] [Abstract][Full Text] [Related]
55. Association between personality traits and Escitalopram treatment efficacy in panic disorder. Võhma Ü; Raag M; Tõru I; Aluoja A; Maron E Nord J Psychiatry; 2017 Aug; 71(6):433-440. PubMed ID: 28472591 [TBL] [Abstract][Full Text] [Related]
56. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Dannon PN; Iancu I; Lowengrub K; Gonopolsky Y; Musin E; Grunhaus L; Kotler M Clin Neuropharmacol; 2007; 30(6):326-34. PubMed ID: 18090457 [TBL] [Abstract][Full Text] [Related]
57. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Lenox-Smith AJ; Jiang Q Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525 [TBL] [Abstract][Full Text] [Related]